IMPACT ovarian cancer capsules authorised in China

IMPACT Therapeutics has received the China NMPA marketing authorisation for Senaparib capsules in treating ovarian cancer.

Jan 18, 2025 - 06:00

IMPACT ovarian cancer capsules authorised in China

IMPACT Therapeutics has received the China NMPA marketing authorisation for Senaparib capsules in treating ovarian cancer.

Read the original article

Tags:

Previous Article

Shionogi awarded $375m from HHS for preventative Covid-19 injectable

Novo Nordisk’s Ozempic named in latest Medicare price negotiations

What's Your Reaction?

0

Like

0

Dislike

0

Love

0

Funny

0

Angry

0

Sad

0

Wow

Related Posts

Pharmaceutical Technology Excellence Awards 2023: KAI C...

Jan 5, 2024

No pain data yet from Vertex, and sky high deal expectations at JPM 2024

No pain data yet from Vertex, and sky high deal expecta...

Jan 8, 2024

Synendos set to study endocannabinoid inhibitor for neuropsychiatric conditions

Synendos set to study endocannabinoid inhibitor for neu...

Jan 19, 2024